August 28, 2014 Isis Pharmaceuticals, Inc. announced the initiation of a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS). FCS is a …
Disease Awareness Initiative Launched for Familial Chylomicronemia Syndrome (FCS)
FCS is rare genetic condition that causes severe hypertriglyceridemia and increases the risk of pancreatitis. Rare Disease Communications has created a new web site to …